Ri. Lalisang et al., Dose-dense epirubicin and paclitaxel with G-CSF: a study of decreasing intervals in metastatic breast cancer, BR J CANC, 82(12), 2000, pp. 1914-1919
Anthracyclines and taxanes are very effective drugs in the treatment of adv
anced breast cancer. With G-CSF support, the dose-intensity of this combina
tion can be increased by reducing the interval between chemotherapy cycles,
the so-called 'shortening of cycle time'. We treated 36 patients with adva
nced breast cancer in a multicentre phase I/II study. The treatment regimen
consisted of epirubicin 75 mg m(-2) followed by paclitaxel 135 mg m(-2) (3
h) in combination with G-CSF. At least six patients were treated in each c
ohort and were evaluated over the first three cycles. Starting at an interv
al of 14 days, in subsequent cohorts of patients the interval could be shor
tened to 10 days. An 8-day interval was not feasible due mainly to incomple
te neutrophil recovery at the day of the next scheduled cycle. In the 10-da
y interval cohort it was feasible to increase the paclitaxel dose to 175 mg
m(-2). The haematological and non-haematological toxicity was relatively m
ild. No cumulative myelosuppression was observed over at least three consec
utive cycles. In combination with G-CSF, epirubicin 75 mg m(-2) and paclita
xel 175 mg m(-2) could be safely administered every 10 days over at least t
hree cycles, enabling a dose intensity of 52 and 122 mg m(-2) per week, res
pectively. (C) 2000 Cancer Research Campaign.